Journal
CYTOTHERAPY
Volume 16, Issue 6, Pages 713-733Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2013.10.002
Keywords
cancer treatment; CAR T cells; genetic modification of T cells; immunotherapy
Categories
Funding
- Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- U.S. National Institutes of Health National Cancer Institute
- National Heart, Lung and Blood Institute
- Department of Defense
- Leukemia and Lymphoma Research Fund
- Alex's Lemonade Stand
- V Foundation
- Dana Foundation
- James S. McDonnell Foundation
- Adrienne Helis Medical Research Foundation
Ask authors/readers for more resources
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available